8-K - Neumora Therapeutics, Inc. Common Stock | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Neumora Therapeutics reported Q4 2025 net loss of $59.4 million and full-year 2025 net loss of $236.9 million, with cash of $182.5 million funding operations into Q3 2027.

Key Takeaways

1Net loss for Q4 2025 was $59.4 million versus $58.8 million in Q4 2024; full-year 2025 net loss was $236.9 million versus $243.8 million in 2024.

2R&D expenses decreased to $44.7 million in Q4 2025 from $45.9 million in Q4 2024, and to $176.1 million for full-year 2025 from $200.9 million in 2024.

3Cash, cash equivalents and marketable securities totaled $182.5 million as of December 31, 2025, down from $307.6 million at December 31, 2024.

4KOASTAL-2 and KOASTAL-3 studies were fully enrolled in Q1 2026 with joint topline data readout expected in Q2 2026.

5NMRA-898 was selected as lead program in M4 franchise based on promising Phase 1 results demonstrating approximately 80-100 hour half-life.

6NMRA-215 remains on track for clinical study initiation in Q1 2027 following completion of 28-day and 13-week toxicology studies.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18

Financial Results

9.01

Financial Statements and Exhibits. | Exhibit Number | | Description | |---|---|---| | 99.1 | | Press Release dated March 30, 2026 | | 104 | | Cover Page Interac

Exhibits Only

Source Document

Results of Operations

Q4 FY2025

Metric	Value	Basis	Prior Period
Net Loss	$-59.45	GAAP	$-58.82
Diluted EPS	$-0.35	GAAP	$-0.37
Research and Development Expense	$44.67	GAAP	$45.91
General and Administrative Expense	$13.81	GAAP	$17.01

Exhibits (2)

8-K

99.1

EX-99.1